Migraine aura increases the risk of atrial fibrillation, which may lead to a stroke

December 21, 2018

A typical migraine aura consists of a visual disturbance (partial loss of vision, flickering lights, zigzags, etc) which lasts 15 to 60 minutes and precedes the headache. Auras can also occur without a headache. Auras occurs in 15 to 20% of migraine sufferers and those who experience them have a slightly higher risk of strokes. The reason for this increased risk has remained unclear.

A study just published in Neurology suggests a possible explanation. The study followed 11,939 participants, of whom 426 reported migraines with visual aura, 1,090 migraine without visual aura, 1,018 non-migraine headache, and 9,405 had no headache. Over a 20-year follow-up period, 232 (15%) of 1,516 with migraine developed atrial fibrillation, a type of cardiac arrhythmia (irregular heart beat). Migraine with visual aura was associated with 1.3 times higher risk of atrial fibrillation compared to no headache as well as 1.4 times higher when compared to migraine without visual aura.

Atrial fibrillation is very common and carries a fivefold increase in the risk of stroke compared to those with normal heart rhythm. This risk is even higher in those who are older than 65 years, in women, those who have congestive heart failure, had a prior stroke or transient ischemic attack, hypertension, diabetes and vascular disease. You can’t do anything about your age or being a woman, but good control of hypertension and diabetes (and exercise, weight control, and not smoking) can lower this risk. Patients with atrial fibrillation are usually treated with an anticoagulant (blood thinner), such as apixaban (Eliquis), which can prevent strokes.

Written by
Alexander Mauskop, MD
Continue reading
May 21, 2026
Research
Your Brain Has Many Pathways, And TMS Can Now Use Them
A groundbreaking University of Iowa study shows that personalized fMRI-guided TMS can now reach and modulate the deep hippocampus — the brain’s command center for memory, emotion, and migraine — without surgery or heavy medications. By mapping each patient’s unique neural pathways, TMS delivers precise stimulation to surface “control points” that influence deep brain structures. Generic approaches barely work, but individualized targeting produces clear, measurable changes. At our headache clinic, we combine TMS and fMRI to offer this advanced, personalized treatment for migraines, depression, PTSD, anxiety, and more.
Read article
May 10, 2026
Research
Elismetrep: A Promising New Experimental Migraine Treatment
Elismetrep is a promising experimental migraine medication that targets the TRPM8 pathway rather than serotonin or CGRP. Early clinical trials suggest it may offer a new option for patients who do not respond well to current treatments.
Read article
May 6, 2026
Alternative Therapies
New Research on Brain Excitability and TMS Treatment for Migraine
New research shows how the brain dynamically regulates excitability in real time—and why this matters for transcranial magnetic stimulation (TMS) as a treatment for migraine.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe